LY2784544 is identified as being highly selective for JAK2-V617F and has advanced into human clinical trials for the treatment of several myeloproliferative disorders.

LY2228820 is a novel and potent p38MAPK inhibitor with potent antiinflammatory activity.

LY294002 is a PI3k inhibitor (cell IC50 about 10 ??M) and a casein kinase II inhibitor.

LY294002 is a PI3k inhibitor (cell IC50 about 10 ??M) and a casein kinase II inhibitor.

LY335979 (Zosuquidar trihydrochloride) is a potent highly selective P-gp inhibitor.

LY335979 (Zosuquidar trihydrochloride) is a potent highly selective P-gp inhibitor.

LY335979 (Zosuquidar trihydrochloride) is a potent highly selective P-gp inhibitor.

LY315920 (Varespladib) is an inhibitor of the IIa, V, and X isoforms of secretory phospholipase A2 (sPLA2).

LY315920 (Varespladib) is an inhibitor of the IIa, V, and X isoforms of secretory phospholipase A2 (sPLA2).